ImmuPharma (LON:IMM) Trading Up 56.4% – Still a Buy?

Shares of ImmuPharma plc (LON:IMM) traded up 56.4% on Tuesday . The company traded as high as GBX 8.70 ($0.12) and last traded at GBX 8.06 ($0.11). 44,629,688 shares were traded during mid-day trading, an increase of 509% from the average session volume of 7,327,748 shares. The stock had previously closed at GBX 5.16 ($0.07).

ImmuPharma Stock Down 3.2%

The stock has a market capitalization of £38.98 million, a PE ratio of -876.40 and a beta of 1.53. The firm has a 50 day moving average price of GBX 2.38 and a 200-day moving average price of GBX 2.70.

ImmuPharma (LON:IMM) last announced its quarterly earnings data on Wednesday, August 6th. The company reported GBX (0.38) earnings per share (EPS) for the quarter. ImmuPharma had a negative return on equity of 131.41% and a net margin of 3,519.56%. Equities analysts expect that ImmuPharma plc will post -339.0000022 earnings per share for the current fiscal year.

About ImmuPharma

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.